- Molecular NameMilnacipran
- Synonym(-)-milnacipran; F 2207; Midalcipran; milnacipran; Milnacipranum [latin]
- Weight244.382
- Drugbank_IDDB04896
- ACS_NO92623-85-3
- Show 2D model
- LogP (experiment)2.03
- LogP (predicted, AB/LogP v2.0)2.55
- pkaN/A
- LogD (pH=7, predicted)-1.75
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)0.61
- LogSw (predicted, AB/LogsW2.0)0.03
- Sw (mg/ml) (predicted, ACD/Labs)2.05
- No.of HBond Donors2
- No.of HBond Acceptors2
- No.of Rotatable Bonds6
- TPSA29.26
- StatusFDA approved
- AdministrationN/A
- PharmacologyA psychoactive drug which functions as a serotonin-norepinephrine reuptake inhibitor (SNRI). It is used for the treatment of clinical depression and fibromyalgia.
- Absorption_valueN/A
- Absorption (description)Milnacipran is well absorbed after oral dosing and has a bioavailability of 85%. Meals do not have an influence on the rapidity and extent of absorption. Peak plasma concentrations are reached 2 hours after oral dosing.
- Caco_2N/A
- Bioavailability84.0
- Protein binding13.0
- Volume of distribution (VD)5.5 L/kg (healthy); 6.3 L/kg (patients with liver impairment)
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmOnly traces of active metabolites are found. Enzymes of the CYP class do not play a role in the metabolism of Milnacipran so that the risk of interactions with drugs metabolized by CYP enzymes is minimal.
- Half life7 h
- ExcretionRenal
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityN/A
- LD50 (rat)N/A
- LD50 (mouse)N/A